Dalwadi Shraddha M, Hunt Andrew, Bonnen Mark D, Ghebre Yohannes T
Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.
Front Oncol. 2023 May 18;13:1198284. doi: 10.3389/fonc.2023.1198284. eCollection 2023.
Historically, the effort by academia and industry to develop new chemical entities into lifesaving drugs has limited success in meeting the demands of today's healthcare. Repurposing drugs that are originally approved by the United States Food and Drug Administration or by regulatory authorities around the globe is an attractive strategy to rapidly develop much-needed therapeutics for oncologic indications that extend from treating cancer to managing treatment-related complications. This review discusses computational approaches to harness existing drugs for new therapeutic use in oncology.
从历史上看,学术界和制药行业致力于将新的化学实体开发成挽救生命的药物,但在满足当今医疗保健需求方面取得的成功有限。重新利用最初由美国食品药品监督管理局或全球监管机构批准的药物,是一种颇具吸引力的策略,可迅速开发出治疗肿瘤所需的疗法,涵盖从治疗癌症到处理治疗相关并发症等多个方面。本综述讨论了利用现有药物在肿瘤学中进行新治疗用途的计算方法。